Source: ||Streptomyces aureofaciens|
|Synonyms||2E, 4E, 7E-Undecatriene-1-triazene|
|Description: ||Triacsin C, an analog of polyunsaturated fatty acid. A potent vasodilator.|
|CAS number: ||76896-80-5|
|Merck index: || |
|Molecular weight: ||207.3|
|Molecular Formula: ||C11H17N3O|
|Appearance: ||Off white powder|
|Purity: ||At least 94% by TLC, HPLC|
|Melting point:|| |
|Solubility:||Clear solution at 25 mg/ml of DMSO|
|Storage:||-20°C. Protect from light.|
|Applications:||Selectively inhibits arachidonoyl-CoA synthetase in intact cells.|
Inhibits the nonspecific acyl-CoA synthetase in cell sonicates
Inhibits neutrophil functions.
|Related products:||To the best of our knowledge, toxicological properties of Triacsin C have not been fully investigated. All uncharacterized chemicals should be treated suspected toxins. |
|Classification:||polyunsaturated fatty acid analog.|
arachidonoyl-CoA synthetase inhibitor
| ||For Research use only. Not for Human or Drug use|
GMP/API grade available on request
Triacsin C by Fermentek is not produced from or contains any ingredients from animal origin.
No genetically modified organisms are used.
| ||Hartman EJ, Omura S, Laposata M.|
Triacsin C: a differential inhibitor of arachidonoyl-CoA synthetase and nonspecific long chain acyl-CoA synthetase.
Prostaglandins. 1989 Jun;37(6):655-71.
| ||Igal RA, Wang P, Coleman RA.|
Triacsin C blocks de novo synthesis of glycerolipids and cholesterol esters but not recycling of fatty acid into phospholipid: evidence for functionally separate pools of acyl-CoA.
Biochem J. 1997 Jun 1;324 ( Pt 2):529-34.
| ||Oh-ishi S, Yamaki K, Abe M, Tomoda H, Omura S.|
The acyl-CoA synthetase inhibitor triacsin C enhanced eicosanoid release in leukocytes.
Jpn J Pharmacol. 1992 Jul;59(3):417-8.
| ||Iorio E, Di Vito M, Spadaro F, Ramoni C, Lococo E, Carnevale R, Lenti L, Strom R, Podo F.|
Triacsin C inhibits the formation of 1H NMR-visible mobile lipids and lipid bodies in HuT 78 apoptotic cells.
Biochim Biophys Acta. 2003 Oct 20;1634(1-2):1-14
Triacsin C on Wikipedia
Anti-atherosclerotic Activity of Triacsin C, an
Acyl-CoA Synthetase Inhibitor
The Journal of Antibiotics 61, 318-321 (May
...When triacsin C
was orally administered (10 mg/kg/day), the
atherosclerotic areas were significantly reduced
by 86% in aorta and 36% in hearts. The results
strongly suggested that triacsin C shows anti-atherogenic
activity by inhibiting acyl-CoA synthetase